
CLAIMS

1. An agonist antibody that binds to OX40 and the TLR4 agonist CRX-601 for simultaneous or sequential, in any order, use in treating cancer in a human patient;

wherein the agonist antibody that binds to OX40 is a humanized monoclonal antibody comprising: (a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 1; (b) a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2; (c) a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 3; (d) a light chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 7; (e) a light chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 8; and (f) a light chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 9; and

wherein CRX-601 has the formula shown below:



.

2. An agonist antibody that binds to OX40 and the TLR4 agonist CRX-601 for use according to Claim 1, wherein the agonist antibody that binds to OX40 is an antibody comprising a heavy chain variable region comprising an amino acid sequence with at least 90% identity to an amino acid sequence chosen from: SEQ ID NO: 4 and SEQ ID NO: 5, wherein the antibody further comprises a light chain variable region comprising an amino acid sequence with at least 90% identity to an amino acid sequence chosen from: SEQ ID NO: 10 and SEQ ID NO: 11.

3. An agonist antibody that binds to OX40 and the TLR4 agonist CRX-601 for use according to Claims 1 or 2, wherein the agonist antibody that binds to OX40 is an antibody comprising a heavy chain variable region comprising the amino acid sequence as set forth in SEQ ID NO: 5; and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11.

4. An agonist antibody that binds to OX40 and the TLR4 agonist CRX-601 for use according to any one of Claims 1 to 3, wherein the agonist antibody that binds to OX40 and the TLR4 agonist are to be administered to the patient in a route chosen from: systemically; intravenously; and intratumorally.

5. An agonist antibody that binds to OX40 and the TLR4 agonist CRX-601 for use according to Claim 4, wherein the agonist antibody that binds to OX40 is to be administered intravenously, and the TLR4 agonist is to be administered intratumorally.

6. An agonist antibody that binds to OX40 and the TLR4 agonist CRX-601 for use according to any one of the preceding claims, wherein the cancer is chosen from: liquid tumors and solid tumors.

7. An agonist antibody that binds to OX40 and the TLR4 agonist CRX-601 for use according to any one of the preceding claims, wherein the cancer is chosen from: melanoma; lung cancer; kidney cancer; breast cancer; head and neck cancer; colon cancer; colorectal cancer (CRC); ovarian cancer; pancreatic cancer; liver cancer; prostate cancer; bladder cancer; gastric cancer; hematopoetic tumors; leukemia; and lymphoma.

8. An agonist antibody that binds to OX40 and the TLR4 agonist CRX-601 for use according to Claim 7, wherein the lung cancer is non-small cell lung cancer (NSCLC).

9. An agonist antibody that binds to OX40 and the TLR4 agonist CRX-601 for use according to Claim 7, wherein the kidney cancer is renal cell carcinoma (RCC).

10. An agonist antibody that binds to OX40 and the TLR4 agonist CRX-601 for use according to Claim 7, wherein the breast cancer is metastatic breast cancer or triple-negative breast cancer (TNBC).

11. An agonist antibody that binds to OX40 and the TLR4 agonist CRX-601 for use according to Claim 7, wherein the liver cancer is hepatocellular carcinoma (HCC).

12. An agonist antibody that binds to OX40 and the TLR4 agonist CRX-601 for use according to Claim 7, wherein the leukemia is chronic lymphocytic leukemia (CLL).

13. An agonist antibody that binds to OX40 and the TLR4 agonist CRX-601 for use according to Claim 7, wherein the lymphoma is non-Hodgkins lymphoma (NHL).

14. A pharmaceutical composition or kit comprising a therapeutically effective amount of an agonist antibody that binds to OX40, as defined in any one of Claims 1 to 3, and the TLR4 agonist, CRX-601, as defined in Claim 1.

15. The pharmaceutical composition or kit as claimed in Claim 14, together with at least one of: a pharmaceutically acceptable carrier and a pharmaceutically acceptable diluent.